Keywords: دامنه تیروزین کیناز; CBL; casitas B-lineage lymphoma; CtxR; cetuximab-resistant; CtxS; cetuximab-sensitive; CRC; colorectal cancer; EGF; epidermal growth factor; EGFR; epidermal growth factor receptor; EMT; epithelial to mesenchymal transition; EPR; epiregulin; FDA; food and
مقالات ISI دامنه تیروزین کیناز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دامنه تیروزین کیناز; Piebaldism; KIT gene; Tyrosine kinase domain; Mutation analysisPiébaldisme; Gène KIT; Domaine tyrosine kinase; Analyse mutationnelle
Keywords: دامنه تیروزین کیناز; ARMS; alveolar rhabdomyosarcoma; BSS; Beare Stevenson cutis gyrata syndrome; CFS; chromosomal fragile site; CC; coiled coil domain; EMS; 8p11 myeloproliferative syndrome (EMS); ERMS; embryonal rhabdomyosarcoma; FN; fibronectin domain; Ig; immunoglobulin-l
Keywords: دامنه تیروزین کیناز; NGS; CML; ALL; BCR-ABL1; Tyrosine kinase domain; TKI;
Keywords: دامنه تیروزین کیناز; AML; acute myeloid leukemia; APL; acute promyelocytic leukemia; ASX; additional sex combs; BM; bone marrow; bZIP; leucine zipper; C/EBPα; CCAAT/enhancer binding protein α; CN-AML; normal karyotype-AML; CR; complete remissions; DFS; disease-free survival
FLT3 receptor/CD135 expression by flow cytometry in acute myeloid leukemia: Relation to FLT3 gene mutations and mRNA transcripts
Keywords: دامنه تیروزین کیناز; AML; acute myeloid leukemia; ANOVA; analysis of variance; BM; bone marrow; CT; cycle threshold; DNA; deoxyribonucleic acid; FAB; French-American-British; FISH; fluorescence in situ hybridization; FLK2; fetal liver tyrosine kinase 2; FLT3; FMS-like tyrosin
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
Keywords: دامنه تیروزین کیناز; ALK; anaplastic lymphoma kinase; CT; computed tomography; E-BUS; endobronchial ultrasound; IHC; immunohistochemistry; MRI; magnetic resonance imaging; NGS; next-generation sequencing; NSCLC; non-small cell lung cancer; PD; progression of disease; PR; part
Identification of small molecule activators for ErbB 4 receptor to enhance oligodendrocyte regeneration by in silico approach
Keywords: دامنه تیروزین کیناز; ADMET; adsorption distribution metabolism excretion toxicity; BBB; blood brain barrier; BS; bioavailability score; CNS; central nervous system; CT; C-terminal tail; ECD; extracellular domain; EGF; epidermal growth factor; ESOL; estimated solubility; EV; E
Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia
Keywords: دامنه تیروزین کیناز; Mnk inhibitor; FLT3 inhibitor; Dual inhibitor; AML; Drug discovery; Anti-leukaemic agent; AML; acute myeloid leukaemia; CDK; cyclin-dependent kinase; eIF; eukaryotic initiation factor; Erk; extracellular signal-regulated kinase; FLT3; Fms-like tyrosine ki
Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics
Keywords: دامنه تیروزین کیناز; RTK; receptor tyrosine kinase; EGF; epidermal growh factor; EGFR; epidermal growth factor receptor; LRIG1; leucin-rich repeats and immunoglobulin-like domains1; MIG; 6mitogen inducible gene 6; RALT; receptor associated late transducer; ERRFI1; ErbB recept
Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia
Keywords: دامنه تیروزین کیناز; ALL; acute lymphoblastic leukemia; APC; allophycocyanin; AML; Acute myeloid leukemia; Bcp-ALL; B-cell precursor ALL; BM; bone marrow; BFM; Berlin-Frankfurt-Munster; cy; cytoplasmatic; DS; diagnosis sample; EGIL; European group for the immunological ch
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome
Keywords: دامنه تیروزین کیناز; Chronic myeloid leukemia; Imatinib mesylate; BCR-ABL dependent mechanisms; Tyrosine kinase domain; Mutation;
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer
Keywords: دامنه تیروزین کیناز; Neoadjuvant therapy; Tyrosine kinase domain; Mutation; Gefitinib; Response biomarker; Proliferation marker; Fibrosis; Inflammatory infiltrate;